Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 2
1992 1
1993 6
1994 4
1995 5
1996 7
1997 6
1998 13
1999 20
2000 24
2001 23
2002 23
2003 17
2004 24
2005 31
2006 21
2007 38
2008 17
2009 20
2010 18
2011 27
2012 29
2013 21
2014 21
2015 39
2016 31
2017 44
2018 39
2019 38
2020 47
2021 47
2022 60
2023 62
2024 33

Text availability

Article attribute

Article type

Publication date

Search Results

786 results

Results by year

Filters applied: . Clear all
Page 1
Precision medicine for human cancers with Notch signaling dysregulation (Review).
Katoh M, Katoh M. Katoh M, et al. Int J Mol Med. 2020 Feb;45(2):279-297. doi: 10.3892/ijmm.2019.4418. Epub 2019 Dec 4. Int J Mol Med. 2020. PMID: 31894255 Free PMC article. Review.
Notch signaling cascades crosstalk with fibroblast growth factor and WNT signaling cascades in the tumor microenvironment to maintain cancer stem cells and remodel the tumor microenvironment. The Notch signaling network exerts oncogenic and tumor-suppressive effects in a …
Notch signaling cascades crosstalk with fibroblast growth factor and WNT signaling cascades in the tumor microenvironment to maintain can …
Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma.
Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K, French D, Go MA, Jack A, Junutula JR, Koeppen H, Lau J, McBride J, Rawstron A, Shi X, Yu N, Yu SF, Yue P, Zheng B, Ebens A, Polson AG. Dornan D, et al. Blood. 2009 Sep 24;114(13):2721-9. doi: 10.1182/blood-2009-02-205500. Epub 2009 Jul 24. Blood. 2009. PMID: 19633198 Free article.
By using flow cytometry, we detected the surface expression of CD79b in almost all non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia patients, suggesting that anti-CD79b-vcMMAE could be widely used in these malignancies. By using NHL cell lines to simulate …
By using flow cytometry, we detected the surface expression of CD79b in almost all non-Hodgkin lymphoma (NHL) and chronic lymphocytic …
Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment.
Liu Y, Barta SK. Liu Y, et al. Am J Hematol. 2019 May;94(5):604-616. doi: 10.1002/ajh.25460. Am J Hematol. 2019. PMID: 30859597 Free article. Review.
DIAGNOSIS: DLBCL is ideally diagnosed from an excisional biopsy of a suspicious lymph node, which shows sheets of large cells that disrupt the underlying structural integrity of the follicle center and stain positive for pan-B-cell antigens, such as CD20 and CD79a. COO is …
DIAGNOSIS: DLBCL is ideally diagnosed from an excisional biopsy of a suspicious lymph node, which shows sheets of large cells that disrupt t …
Anti-CD79b/CD3 bispecific antibody combined with CAR19-T cells for B-cell lymphoma treatment.
Zheng WW, Zhou H, Li P, Ye SG, Abudureheman T, Yang LT, Qing K, Liang AB, Chen KM, Duan CW. Zheng WW, et al. Cancer Immunol Immunother. 2023 Nov;72(11):3739-3753. doi: 10.1007/s00262-023-03526-z. Epub 2023 Sep 14. Cancer Immunol Immunother. 2023. PMID: 37707586 Free PMC article.
When the CD19 antigen was lost or reduced, BV28-OKT3 redirected CAR19-T cells to CD79b(+) CD19(-) lymphoma cells; therefore, BV28-OKT3 overcomes the escape of CD79b(+) CD19(-) lymphoma cells by the killing action of CAR19-T cells in vitro and in vivo. ...Therefore, …
When the CD19 antigen was lost or reduced, BV28-OKT3 redirected CAR19-T cells to CD79b(+) CD19(-) lymphoma cells; therefore, BV28-OKT …
Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas.
Chu F, Cao J, Liu J, Yang H, Davis TJ, Kuang SQ, Cheng X, Zhang Z, Karri S, Vien LT, Bover L, Sun R, Vega F, Green M, Davis RE, Neelapu SS. Chu F, et al. J Immunother Cancer. 2023 Nov 24;11(11):e007515. doi: 10.1136/jitc-2023-007515. J Immunother Cancer. 2023. PMID: 38007239 Free PMC article.
METHODS: We generated a novel anti-CD79b monoclonal antibody by hybridoma method. The specificity of the antibody was determined by testing against isogenic cell lines with human CD79b knock-in or knock-out. ...This CD79b CAR specifically recognized human …
METHODS: We generated a novel anti-CD79b monoclonal antibody by hybridoma method. The specificity of the antibody was determined by t …
Human CD79b(+) neutrophils in the blood are associated with early-stage melanoma.
Meyer MA, Dinh HQ, Alimadadi A, Araujo DJ, Chatterjee N, Gutierrez NA, Zhu YP, Hunter EL, Liang S, Seumois G, Kiosses WB, Catz SD, Vijayanand P, Ottensmeier C, Hedrick CC. Meyer MA, et al. Front Immunol. 2023 Oct 31;14:1224045. doi: 10.3389/fimmu.2023.1224045. eCollection 2023. Front Immunol. 2023. PMID: 38022639 Free PMC article.
Further, we found CD79b(+) neutrophils present in tumors of subjects with head and neck cancer. ...CONCLUSION: Our work suggests that CD79b(+) neutrophils are associated with early-stage melanoma....
Further, we found CD79b(+) neutrophils present in tumors of subjects with head and neck cancer. ...CONCLUSION: Our work sugges …
Mechanism of CD79A and CD79B Support for IgM+ B Cell Fitness through B Cell Receptor Surface Expression.
Huse K, Bai B, Hilden VI, Bollum LK, Våtsveen TK, Munthe LA, Smeland EB, Irish JM, Wälchli S, Myklebust JH. Huse K, et al. J Immunol. 2022 Nov 15;209(10):2042-2053. doi: 10.4049/jimmunol.2200144. J Immunol. 2022. PMID: 36426942 Free PMC article.
We explored the mechanism for IgM surface expression by CRISPR/Cas9-induced deletion of CD79A or CD79B in four B lymphoma cell lines. Deletion of either CD79 protein caused loss of surface IgM in all cell lines and reduced fitness in three. ...Rescue experiments wit …
We explored the mechanism for IgM surface expression by CRISPR/Cas9-induced deletion of CD79A or CD79B in four B lymphoma cell lines. …
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC, Czuczman M, Salles G, Assouline S, Sehn LH, Flinn I, Patel MR, Sangha R, Hagenbeek A, Advani R, Tilly H, Casasnovas O, Press OW, Yalamanchili S, Kahn R, Dere RC, Lu D, Jones S, Jones C, Chu YW, Morschhauser F. Palanca-Wessels MC, et al. Lancet Oncol. 2015 Jun;16(6):704-15. doi: 10.1016/S1470-2045(15)70128-2. Epub 2015 Apr 27. Lancet Oncol. 2015. PMID: 25925619 Clinical Trial.
Polatuzumab vedotin is an antibody-drug conjugate containing an anti-CD79B monoclonal antibody conjugated to the microtubule-disrupting agent monomethyl auristatin E. ...METHODS: In this phase 1, multicentre, open-label study, we enrolled patients with documented NHL or CL …
Polatuzumab vedotin is an antibody-drug conjugate containing an anti-CD79B monoclonal antibody conjugated to the microtubule-disrupti …
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, Codega P, Nichol D, Clark O, Hsieh WY, Rohle D, Rosenblum M, Viale A, Tabar VS, Brennan CW, Gavrilovic IT, Kaley TJ, Nolan CP, Omuro A, Pentsova E, Thomas AA, Tsyvkin E, Noy A, Palomba ML, Hamlin P, Sauter CS, Moskowitz CH, Wolfe J, Dogan A, Won M, Glass J, Peak S, Lallana EC, Hatzoglou V, Reiner AS, Gutin PH, Huse JT, Panageas KS, Graeber TG, Schultz N, DeAngelis LM, Mellinghoff IK. Grommes C, et al. Cancer Discov. 2017 Sep;7(9):1018-1029. doi: 10.1158/2159-8290.CD-17-0613. Epub 2017 Jun 15. Cancer Discov. 2017. PMID: 28619981 Free PMC article. Clinical Trial.
Incomplete tumor responses were associated with mutations in the B-cell antigen receptor-associated protein CD79B. CD79B-mutant PCNSLs showed enrichment of mammalian target of rapamycin (mTOR)-related gene sets and increased staining with PI3K/mTOR activation marker …
Incomplete tumor responses were associated with mutations in the B-cell antigen receptor-associated protein CD79B. CD79B-mutan …
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.
Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, Yang Y, Cole DE, Melani C, Higham CS, Desai JV, Ceribelli M, Chen L, Thomas CJ, Little RF, Gea-Banacloche J, Bhaumik S, Stetler-Stevenson M, Pittaluga S, Jaffe ES, Heiss J, Lucas N, Steinberg SM, Staudt LM, Wilson WH. Lionakis MS, et al. Cancer Cell. 2017 Jun 12;31(6):833-843.e5. doi: 10.1016/j.ccell.2017.04.012. Epub 2017 May 25. Cancer Cell. 2017. PMID: 28552327 Free PMC article.
Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, targets BCR signaling and is particularly active in lymphomas with mutations altering the BCR subunit CD79B and MYD88. We performed a proof-of-concept phase Ib study of ibrutinib monotherapy followed by ibrutinib plus …
Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, targets BCR signaling and is particularly active in lymphomas with mutations altering …
786 results